Exclusive: Following Up Akebia, Johnson & Johnson's Research And License Agreement

By: via Benzinga
On Monday, Akebia Therapeutics Inc (NASDAQ: AKBA) signed a $1 million research and license agreement with Johnson & Johnson (NYSE: ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.